reported that the knockdown of YTHDF1 in dendritic cells could improve cross-priming of CD8+ T cells and cross-presentation of tumor neoantigens, suggesting YTHDF1 served as a critical biomarker in immunotherapy (25). The gene discussed is YTHDF1; the disease is neoplasm.